A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Summary

The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease. The goal of the study is to determine if Dostarlimab therapy alone is an effective treatment that can allow participants to avoid chemotherapy, radiation, and surgery.

Timeline

Start

2023-04-03

Primary completion

2026-11-02

Completion

2029-10-11

Drugs

Indications